Symptom variability in patients with severe COPD: A pan-European crosssectional study

European Respiratory Journal

Volumn 37, Issue 2, 2011, Pages 264-272

  Kessler, R ^a   Partridge, M R ^c   Miravitlles, M ^d   Cazzola, M ^e,f   Vogelmeiere, C ^g   Leynaud, D ^b   Ostinelli, J ^b  

^a HÔPITAL CIVIL   (France)

^b ASTRAZENECA   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f IRCCS SAN RAFFAELE PISANA   (Italy)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Breathlessness; Chronic obstructive pulmonary disease; Symptom variability; Symptoms; Treatment

Indexed keywords

BRONCHODILATING AGENT; GLUCOCORTICOID;

ADULT; AGE; ARTICLE; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COUGHING; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENERAL PRACTITIONER; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; SMOKING CESSATION; SYMPTOM; WHEEZING;

ACTIVITIES OF DAILY LIVING; ADRENAL CORTEX HORMONES; AGED; BRONCHODILATOR AGENTS; CROSS-SECTIONAL STUDIES; DYSPNEA; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 79953645289     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00051110     Document Type: Article

References (30)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. (Pubitemid 47403272)
2. Clark TJ. Diurnal rhythm of asthma. Chest 1987; 91: 137S-141S.
3. Hetzel MR, Clark TJ. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax 1980; 35: 732-738. (Pubitemid 11225282)
4. Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med 1988; 85: 6-8.
5. Haughney J, Partridge MR, Vogelmeier C, et al. Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling. Eur Respir J 2005; 26: 623-629. (Pubitemid 41448659)
6. Lewinsohn HC, Capel LH, Smart J. Changes in forced expiratory volumes throughout the day. Br Med J 1960; 1: 462-464.
7. Postma DS, Koeter GH, vd Mark TW, et al. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest 1985; 87: 653-657.
8. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517.
9. Barnett M. Chronic obstructive pulmonary disease: a phenomenological study of patients' experiences. J Clin Nurs 2005; 14: 805-812. (Pubitemid 41018436)
10. Barr RG, Celli BR, Martinez FJ, et al. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005; 118: 1415.
11. Engstrom CP, Persson LO, Larsson S, et al. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001; 18: 69-76. (Pubitemid 32717433)
12. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072-1079. (Pubitemid 28012076)
13. Jones PW. Quality of life measurement for patients with diseases of the airways. Thorax 1991; 46: 676-682.
14. Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130: 1117-1128.
15. Kessler R, Stahl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006; 130: 133-142. (Pubitemid 44116851)
16. Miravitlles M, Anzueto A, Legnani D, et al. Patient's perception of exacerbations of COPD-the PERCEIVE study. Respir Med 2007; 101: 453-460. (Pubitemid 46196335)
17. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395. (Pubitemid 38624744)
18. Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007; 167: 60-67. (Pubitemid 46072408)
19. Katula JA, Rejeski WJ, Wickley KL, et al. Perceived difficulty, importance, and satisfaction with physical function in COPD patients. Health Qual Life Outcomes 2004; 2: 18.
20. Gilbert C, Martin ML, Hareendran A, et al. Capturing individual variation in the experience of symptoms reported by patients with COPD. Am J Respir Crit Care Med 2007; 175: A15-1004.
21. Willams SJ. Chronic Respiratory Illness. London, Routledge, 1993.
22. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043-2048.
23. Partridge MR, Miravitlles M, Stahl E, et al. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J 2010; 36: 96-104.
24. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-654.
25. Calverley PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855-860. (Pubitemid 37239232)
26. Esteban C, Quintana JM, Aburto M, et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J 2010; 36: 292-300.
27. Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1-11.
28. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124: 474-481. (Pubitemid 37000122)
29. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728-735.
30. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.